BiotechTube

ticagrelor + aspirin

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Myocardial Injury

Conditions

Myocardial Injury

Trial Timeline

Jul 1, 2015 → Jun 1, 2016

NCT ID
NCT02291419

About ticagrelor + aspirin

ticagrelor + aspirin is a approved stage product being developed by AstraZeneca for Myocardial Injury. The current trial status is terminated. This product is registered under clinical trial identifier NCT02291419. Target conditions include Myocardial Injury.

What happened to similar drugs?

20 of 20 similar drugs in Myocardial Injury were approved

Approved (20) Terminated (3) Active (0)
✅AbciximabEli LillyApproved
✅AbciximabEli LillyApproved
✅abciximabEli LillyApproved
✅Ticagrelor + ClopidogrelAstraZenecaApproved
✅Ticagrelor + PlaceboAstraZenecaApproved
✅Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)AstraZenecaApproved
✅clopidogrel and metoprololAstraZenecaApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02291419ApprovedTerminated

Competing Products

20 competing products in Myocardial Injury

See all competitors
ProductCompanyStageHype Score
Butylphthalide + Butylphthalide placeboCSPC Pharmaceutical Group LimitedPhase 3
47
AbciximabEli LillyApproved
43
Prasugrel + ClopidogrelDaiichi SankyoPhase 3
40
Regadenoson + gadofoveset trisodiumAstellas PharmaPhase 2
35
Half-dose of the Tc99-m sestamibi (Cardiolite)Astellas PharmaPre-clinical
18
No interventionAstellas PharmaPre-clinical
22
Empagliflozin + PlaceboEli LillyPhase 3
40
Abciximab + Abciximab placeboEli LillyPhase 3
36
Intracoronary infusion of enriched bone marrow-derived progenitor cells + Placebo medium supplemented with autologous serumEli LillyPhase 3
40
AbciximabEli LillyApproved
43
abciximab placebo; reteplase placebo, abciximab, abciximab + Abciximab; reteplase; abciximab placebo; abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + abciximab placebo; reteplase placebo, abciximab, abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + Abciximab; reteplase; abciximab placebo; abciximabEli LillyPhase 3
40
fibrinolytic therapy or combination reduced fibrinolytic therapyEli LillyPhase 3
40
abciximabEli LillyApproved
43
tenecteplase + enoxaparin + clopidogrelEli LillyPhase 2/3
38
Thrombolytic therapyEli LillyPre-clinical
22
TicagrelorAstraZenecaPre-clinical
26
TicagrelorAstraZenecaPhase 2
31
Dual-antiplatelet therapy + Dual-antiplatelet therapyAstraZenecaPre-clinical
22
Metoprolol- Toprol XL + Metoprolol- LopressorAstraZenecaPhase 1
29
Ticagrelor orodispersible tablets + Ticagrelor standard tabletsAstraZenecaPhase 3
40